Global /Japan /Healthcare /Drug Manufacturers - General /4556
chevron_leftBack
KAINOS Laboratories, Inc. logo

KAINOS Laboratories, Inc.

4556
TSE: 4556 Delayed
2,270JPY 0.1%
14.17 USD
As of 6 June 2026, KAINOS Laboratories, Inc. has a market cap of $63.11M USD, ranking #28884 globally and #2646 in Japan. It ranks #2622 in the Healthcare sector, and #931 in the Drug Manufacturers - General industry.
Global Rank
28884
Country Rank
2646
Sector Rank
2622
Industry Rank
931
Key Stats
Market Cap
$63.11MUSD
10.1B JPY
Revenue (TTM)
$27.72MUSD
4.44B JPY
EBITDA (TTM)
$1.94MUSD
311.32M JPY
Net Income (TTM)
$517.15KUSD
82.76M JPY
EBITDA Margin
7%
Profit Margin
1.9%
PE Ratio
122.2
PS Ratio
2.3
PB Ratio
3.8
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Yukihiro Nagatsu open_in_new
Employees
133
Founded
1975
Website
kainos.co.jp open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
0.1% 0.1% 0.5% 78% 85% 82%

News

Loading...

Markets

Exchange Ticker Price
Tokyo Stock Exchange
MIC: XTKS
PRIMARY
4556
株式会社カイノス
ISIN: JP3205650009
Shares Out.:
4.395M1 Shares Float: 639.783K2
TV:
SA:
YF:
GF:
BA:
MS:
2,270 JPY
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About KAINOS Laboratories, Inc.

KAINOS Laboratories, Inc. engages in the development, manufacture, marketing, distribution, and import/export of pharmaceuticals, diagnostic reagents, and related chemical products in Japan. It is also involved in the development, manufacture, marketing, distribution, and import/export of physical and chemical measurement instruments, and medical supplies, as well as nutrition supplements, foodstuff, animal feed, and related products. The company provides various biochemical clinical testing reagents systems, such as Aqua-auto Kainos CRE-IV Test Kit, a liquid form creatinine measurement reagent kit for various makes of automatic analyzer systems; Aqua-auto Kainos ALB Test Kit, a liquid form reagent kit; and Aqua-auto Kainos UN-II Test Kit, a liquid urea nitrogen measurement reagent kit. In addition, it offers FGF-23 ELISA Kit, a two-site enzyme-linked immunosorbent assay kit for the measurement of FGF-23 in serum. Further, the company provides point of care testing solutions comprising Swiftgene Norovirus GI/GII Kainos for detecting noroviruses; Statmark FLUstick II for detecting type A and type B influenza virus antigens; and Statmark Strep A for detecting Group A beta-hemolytic streptococci. The company was formerly known as DOMS-IATRON Co., Ltd. and changed its name to KAINOS Laboratories, Inc. in July 1975. KAINOS Laboratories, Inc. was founded in 1975 and is headquartered in Tokyo, Japan. As of March 25, 2026, KAINOS Laboratories, Inc. operates as a subsidiary of Denka Company Limited.

Similar Companies

Industry: Drug Manufacturers - General (Japan)
Name
Market Cap diff.
PE
$81.66B
13.07T JPY
129K%
28.9
$52.21B
8.36T JPY
83K%
75.1
$36.84B
5.9T JPY
58K%
15.7
$30.37B
4.86T JPY
48K%
16.2
$25.82B
4.13T JPY
41K%
14.2
$16.91B
2.71T JPY
27K%
13.9
Industry: Drug Manufacturers - General (Global)
Name
Market Cap diff.
PE
LLY
$761.68B
1M%
38.1
JNJ
$547.28B
867K%
26.4
ABBV
$360.63B
571K%
97.4
$324.68B
256.25B CHF
514K%
19.9
AZN
$289.43B
215.59B GBP
458K%
27.6
NOVN
$277.35B
218.9B CHF
439K%
20.5
chevron_leftBack